Maze Therapeutics, Inc. (MAZE)
2025-06-30 | ||||
|---|---|---|---|---|
| License revenue | - | |||
| Research and development | 28,108,000 | |||
| General and administrative | 8,366,000 | |||
| Total operating expenses | 36,474,000 | |||
| (loss) income from operations | -36,474,000 | |||
| Interest and other income, net | 2,795,000 | |||
| (loss) income before income tax expense | -33,679,000 | |||
| Income tax expense | - | |||
| Net (loss) income and comprehensive (loss) income | -33,679,000 | |||
| Earnings per share, basic | -0.77 | |||
| Earnings per share, diluted | -0.77 | |||
| Weighted average number of shares outstanding, basic | 43,797,421 | |||
| Weighted average number of shares outstanding, diluted | 43,797,421 | |||